FDA calls for new warnings on asthma drugs

Share this article:
The FDA on Friday issued a call for tougher new warnings on three asthma medications stating the drugs might cause severe, and sometimes fatal, asthma attacks in some patients.
The warnings would apply to GlaxoSmithKline's Serevent and Advair and Novartis' Foradil, which is marketed in the U.S. by Schering-Plough.
An FDA spokeswoman said in a Wall Street Journal report that the agency wants to issue a black-box warning to Foradil since it is in the same class as Serevent and Advair, which already carry the warning.
The FDA said other drugs should be used first to control asthma and that Serevent, Advair or Foradil should only be used if other therapies fail.
In a statement, GlaxoSmithKline said it disagreed with the FDA's decision stating that treatment guidelines call for patients with moderate to severe asthma to be treated both with short-and long-acting asthma drugs. 
"GSK believes sufficient safety information about these medicines is already in the labels to help guide physicians about their appropriate use," the company said.
Novartis did not comment on labeling changes over Foradil. Schering-Plough told The Journal through a spokeswoman that the company would send out a letter to healthcare professionals describing any changes once the new label is finalized.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...